001451615 000__ 06151cam\a2200589\a\4500
001451615 001__ 1451615
001451615 003__ OCoLC
001451615 005__ 20230310004709.0
001451615 006__ m\\\\\o\\d\\\\\\\\
001451615 007__ cr\un\nnnunnun
001451615 008__ 221203s2022\\\\sz\\\\\\o\\\\\001\0\eng\d
001451615 019__ $$a1352795608
001451615 020__ $$a9783031044021$$q(electronic bk.)
001451615 020__ $$a3031044029$$q(electronic bk.)
001451615 020__ $$z3031044010
001451615 020__ $$z9783031044014
001451615 0247_ $$a10.1007/978-3-031-04402-1$$2doi
001451615 035__ $$aSP(OCoLC)1352971258
001451615 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dYDX$$dOCLCF$$dUKAHL
001451615 049__ $$aISEA
001451615 050_4 $$aRC271.C5
001451615 08204 $$a615.10289$$223/eng/20221208
001451615 24500 $$aCancer drug safety and public health policy :$$ba changing landscape /$$cCharles Bennett, Courtney Lubaczewski, Bartlett Witherspoon, editors.
001451615 260__ $$aCham :$$bSpringer,$$c2022.
001451615 300__ $$a1 online resource (171 p.).
001451615 4901_ $$aCancer treatment and research ;$$vv. 184
001451615 500__ $$a3.1.2 Lessons Learned and Legal Precedent
001451615 500__ $$aIncludes index.
001451615 5050_ $$aIntro -- Preface -- Contents -- Editors and Contributors -- 1 Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years -- 1.1 Introduction -- 1.1.1 FQ Adverse Event Drug Label Warnings -- 1.1.2 FQ Drug Label Changes (See Table 1.1 for Levofloxacin Label Changes) -- 1.1.3 FDA Reports of FQ Adverse Events -- 1.1.4 November 5, 2015, FDA Advisory Committee Meeting Identifies FQAD -- 1.1.5 November 5, 2015, FDA Advisory Committee Votes -- 1.1.6 Boxwell FDA FQ Data Compared with Social Media FQ Reports
001451615 5058_ $$a1.1.7 Gender -- 1.1.8 Specific FQs -- 1.1.9 Duration of FQAD -- 1.1.10 FQAD: Reasons for Which FQ was Prescribed -- 1.1.11 FQAD Specific Events -- 1.1.12 Possible Mechanism of FQ Toxicities -- 1.1.13 Another Possible Pathophysiologic Mechanism: Matrix Metalloproteinase Toxicity -- 1.1.14 FQ-Associated Peripheral Neuropathy -- 1.1.15 Levaquin Clinical Trials Completed Prior to FDA Approval in 1997 -- 1.1.16 2001 FDA FQ Review -- 1.1.17 2003 FDA FQ Review -- 1.1.18 2008 FDA Pediatric Levofloxacin Review -- 1.1.19 2010 Pfizer Report -- 1.1.20 2011 Levaquin Postmarketing Review
001451615 5058_ $$a1.1.21 2013 FDA Review -- 1.1.22 2014-Present Media Reports Regarding FQs -- 1.1.23 2014 FDA Advisory Committee Comments -- 1.1.24 2014 FDA Dear Healthcare Professional Letters -- 1.1.25 2014 Citizen Petition -- 1.1.26 2014 Meeting with U.S. Senate Health Committee -- 1.1.27 2015 Meeting with FDA -- 1.1.28 2015 FQ Case Studies -- 1.1.29 2015 FDA Advisory Committee Meeting -- 1.1.30 2015 FDA Listening Session -- 1.1.31 2016 FQ Neuropsychiatric Study -- 1.1.32 2016 FQ Label Updates -- 1.1.33 2016 FDA Response to Citizen Petition -- 1.1.34 2018 FQ Nature Article -- 1.1.35 2019 Citizen Petition
001451615 5058_ $$a1.1.36 2019 FQ Neuropsychiatric Toxicity Study -- 1.2 Discussion -- 1.3 Conclusions -- 1.3.1 Recommendations -- 1.3.2 Significance of This FQ Study -- 1.4 REMS Request -- References -- 2 Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions -- 2.1 Introduction -- 2.1.1 Regulatory Approval for Epoetin Biosimilar in the United States -- 2.1.2 Chemistry, Manufacturing, and Controls -- 2.1.3 Biological Activity -- 2.1.4 Pharmacology/Toxicology -- 2.1.5 Immunogenicity -- 2.1.6 Clinical Pharmacology -- 2.1.7 Clinical Efficacy and Safety
001451615 5058_ $$a2.1.8 Risk Evaluation and Mitigations Strategy (REMS) -- 2.1.9 Extrapolation -- 2.1.10 Findings of the Oncology Drug Advisory Committee (ODAC) of the FDA -- 2.1.11 Patents and Litigation -- 2.1.12 Naming and Labeling -- 2.1.13 Interchangeability -- 2.1.14 Substitution -- 2.1.15 Pharmacovigilance and Immunogenicity -- 2.1.16 Lessons from the European Union (EU) Countries -- 2.1.17 Lessons from Japan -- 2.2 Conclusions -- References -- 3 Policing of Drug Safety Information Dissemination Under the False Claims Act -- 3.1 Introduction -- 3.1.1 The Settlement
001451615 506__ $$aAccess limited to authorized users.
001451615 520__ $$aThis book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention these fines are playing an important role in changing the landscape for pharmaceutical safety.
001451615 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed December 8, 2022).
001451615 650_0 $$aAntineoplastic agents$$xSafety measures.
001451615 650_0 $$aCancer$$xTreatment.
001451615 650_0 $$aPharmaceutical policy.
001451615 650_0 $$aMedical policy.
001451615 655_0 $$aElectronic books.
001451615 7001_ $$aBennett, Charles.
001451615 7001_ $$aLubaczewski, Courtney.
001451615 7001_ $$aWitherspoon, Bartlett.
001451615 77608 $$iPrint version:$$aBennett, Charles$$tCancer Drug Safety and Public Health Policy$$dCham : Springer International Publishing AG,c2023$$z9783031044014
001451615 830_0 $$aCancer treatment and research ;$$vv. 184.
001451615 852__ $$bebk
001451615 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-04402-1$$zOnline Access$$91397441.1
001451615 909CO $$ooai:library.usi.edu:1451615$$pGLOBAL_SET
001451615 980__ $$aBIB
001451615 980__ $$aEBOOK
001451615 982__ $$aEbook
001451615 983__ $$aOnline
001451615 994__ $$a92$$bISE